← All trials
NCT06012435
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Nov 30, 2026
- Completion date
- Jan 31, 2029
- First posted
- Aug 25, 2023
- Last posted
- Aug 25, 2023
- Enrollment
- 560
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seattle GeneticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.